{{ e.body }}
{{ e.hrefLabel }} ↗RLRL and Atropine — Concurrent Use Is Contraindicated
The cited device instructions list a dilated pupil and medicines such as atropine as contraindications. For that device, RLRL and atropine must not be used concurrently.
A wider aperture changes the exposure, not the device setting.
{{ m.body }}
Each level answers a different question.
Keeping consensus, radiometry, clinical data and device documentation apart is what makes the conclusion auditable.
Washout is not a calendar date. It is confirmation that the physiological response has returned.
A published interview with Prof. Mingguang He carries the recommendation to stop atropine at least two weeks before starting RLRL.[5] A fixed interval is a starting point for the discussion, not a substitute for examination: mydriasis and reduced light response resolve at different rates depending on concentration and exposure history.
Whether atropine is stopped, how long the transition lasts and when RLRL begins are decisions for the treating clinician.
What the comparative trials do not prove.
A randomised trial comparing repeated low-level red light against low-dose atropine tested which arm slowed progression more.[6] It did not test the two used together, and a comparative efficacy result cannot be read as a safety result for concurrent use.
Every level of the argument, with its source.
This material is educational and organises sources. It does not replace an ophthalmological examination, qualification for therapy, or the instructions for use of a specific medical device. Stopping atropine, the length of the transition period and the start of RLRL are decided by a clinician.
The complete documentation of this contraindication — device instructions, radiometry, consensus wording and the clinical commentary — is held in Polish on Krótkowzroczność.pl. This page is a short international synthesis of it, not a translation.
FULL POLISH EVIDENCE DOSSIER ↗